We also identified that ADCs against CD71, PTK7, CD74, SLC44A4 and LIV‐1 were not under evaluation in breast, colorectal, prostate and gastric cancer, which suggests potential opportunities for evaluation. Here, SLC39A6 is linked to gastric cancer.